What is the 13F Pro Quality Score for STIM?

13F Pro ranks Neuronetics, Inc. (STIM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STIM's current score at https://13fpro.ai/research/STIM (free sign-up required for the full ranking).

Where does 13F Pro source STIM data?

All Neuronetics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Neuronetics, Inc. files with the SEC under CIK 1227636. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STIM in?

Neuronetics, Inc. (STIM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STIM research updated on 13F Pro?

STIM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neuronetics, Inc.(STIM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1227636 STIM stock profile & AI dashboard →

13F Pro Quality Score

31.3/100

Rank #2,321 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.1/100

Profitability

15.1/100

Balance Sheet

7.5/100

Earnings Quality

30.0/100

Free Cash Flow

13.3/100

Institutional Flow

18.5/100

Revenue Scale

20.7/100

Dilution Risk

27.3/100

STIM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Neuronetics, Inc. (STIM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STIM at 31.3/100 on a 32-signal composite quality model, placing it at rank #2,321 of 2,879 stocks — the bottom half of the AI-ranked universe. STIM scores in the top quartile across revenue growth (91.1). Areas of concern include balance sheet strength (7.5) and free cash flow (13.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Neuronetics, Inc. reports quarterly revenue of $34.5M, net income of $-10.8M, an operating margin of -26.1%. Top institutional holders of STIM by reported 13-F value include Madryn Asset Management,, UBS Group AG, BALYASNY ASSET MANAGEMENT L.P., based on the most recent SEC filings. STIM trades on the Nasdaq exchange and files with the SEC under CIK 1227636. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuronetics, Inc. directly from SEC EDGAR. Neuronetics, Inc.'s 13F Pro composite quality score has ranged between 14 and 36 since 2021, currently 31.3 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$34.5M

Net Income

Q1 2026

$-10.8M

Free Cash Flow

Q1 2026

$-9.6M

Operating Margin

Q1 2026

-26.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+99.2% YoY

$149.2MFY 2025

FY20 $49.2MFY22 $65.2MFY24 $74.9MFY25 $149.2M

Net Income

+10.8% YoY

$-39.0MFY 2025

FY20 $-27.5MFY22 $-37.2MFY24 $-43.7MFY25 $-39.0M

Operating Income

+9.0% YoY

$-31.4MFY 2025

FY20 $-22.3MFY22 $-35.1MFY24 $-34.6MFY25 $-31.4M

EPS (Diluted)

+57.2% YoY

$-0.59FY 2025

FY20 $-1.46FY22 $-1.38FY24 $-1.38FY25 $-0.59

Total Assets

+0.5% YoY

$141.6MFY 2025

FY20 $78.7MFY22 $116.9MFY24 $140.9MFY25 $141.6M

Total Debt

+19.3% YoY

$65.8MFY 2025

FY20 $34.6MFY22 $49.1MFY24 $55.2MFY25 $65.8M

Op. Cash Flow

+34.2% YoY

$-20.4MFY 2025

FY20 $-28.4MFY22 $-30.7MFY24 $-31.0MFY25 $-20.4M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$149.2M +99.2%	$74.9M +14.9%	$65.2M +32.4%	$49.2M -21.4%	$62.7M +18.7%	$52.8M
Net Income	$-39.0M +10.8%	$-43.7M -17.6%	$-37.2M -35.4%	$-27.5M +5.5%	$-29.0M -20.5%	$-24.1M
Operating Income	$-31.4M +9.0%	$-34.6M +1.6%	$-35.1M -57.4%	$-22.3M +17.2%	$-26.9M -35.8%	$-19.8M
EPS (Diluted)	$-0.59 +57.2%	$-1.38 +0.0%	$-1.38 +5.5%	$-1.46 +7.6%	$-1.58	—
Total Assets	$141.6M +0.5%	$140.9M +20.5%	$116.9M +48.6%	$78.7M -21.5%	$100.2M -14.4%	$117.0M
Total Debt	$65.8M +19.3%	$55.2M +12.4%	$49.1M +41.8%	$34.6M -18.3%	$42.4M +39.5%	$30.4M
Operating Cash Flow	$-20.4M +34.2%	$-31.0M -1.0%	$-30.7M -8.1%	$-28.4M +6.8%	$-30.5M -48.0%	$-20.6M

AI Insight: STIM Financial Trends

Revenue surged 163% from Q2 2024 to Q2 2025 peak, but Q1 2026 showed concerning 19% sequential decline amid persistent losses.

• Revenue grew from $16M in Q2 2024 to $42M in Q4 2025, representing 163% growth over six quarters.

• Operating losses narrowed significantly from $9M in Q2 2024 to $5M in Q4 2025 before widening to $9M in Q1 2026.

• Operating cash flow improved from persistent $5M outflows to $1M positive in Q4 2025.

• Total debt decreased from $73M in Q2 2024 to $61M in Q1 2026.

⚠ Revenue dropped 19% sequentially from $42M in Q4 2025 to $34M in Q1 2026, breaking growth momentum.

⚠ Equity declined from $35M in Q1 2025 to $13M in Q1 2026 amid continued losses.

⚠ Operating cash flow swung from $1M positive in Q4 2025 to $9M negative in Q1 2026.

AI Insight: STIM Ratio Trends

Operating margin improved significantly from -51.7% in Q2 2024 to -12.1% in Q4 2025, but deteriorated sharply to -26.1% in Q1 2026.

• Operating margin improved 39.6pp from Q2 2024 (-51.7%) to Q4 2025 (-12.1%), showing meaningful progress toward profitability.

• ROIC steadily improved from -55.8% in Q3 2024 to -22.9% in Q4 2025, indicating better capital efficiency.

• Debt-to-equity ratio declined from 4.90 in Q3 2024 to 1.56 in Q1 2025, demonstrating improved leverage profile.

⚠ Operating margin deteriorated 14pp from Q4 2025 (-12.1%) to Q1 2026 (-26.1%), reversing recent improvement trend.

⚠ Debt-to-equity ratio jumped from 2.94 in Q4 2025 to 4.62 in Q1 2026, signaling increased leverage.

Get alerted when STIM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neuronetics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STIM

Madryn Asset Management, LP
$26.8M18,475,893 sh
UBS Group AG
$4.2M2,870,598 sh
BALYASNY ASSET MANAGEMENT L.P.
$4.0M2,743,768 sh
BlackRock, Inc.
$3.4M2,318,537 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.0M2,047,975 sh
Lane Generational LLC
$2.6M1,774,624 sh
FourWorld Capital Management LLC
$2.2M1,489,322 sh
MASTERS CAPITAL MANAGEMENT LLC
$1.4M1,000,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4M958,989 sh
STATE STREET CORP
$1.2M842,547 sh

Fund	Value	Shares
Madryn Asset Management, LP	$26.8M	18,475,893
UBS Group AG	$4.2M	2,870,598
BALYASNY ASSET MANAGEMENT L.P.	$4.0M	2,743,768
BlackRock, Inc.	$3.4M	2,318,537
VANGUARD CAPITAL MANAGEMENT LLC	$3.0M	2,047,975
Lane Generational LLC	$2.6M	1,774,624
FourWorld Capital Management LLC	$2.2M	1,489,322
MASTERS CAPITAL MANAGEMENT LLC	$1.4M	1,000,000
GEODE CAPITAL MANAGEMENT, LLC	$1.4M	958,989
STATE STREET CORP	$1.2M	842,547

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STIM on your watchlist

Track score changes the day Neuronetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STIM a good stock to buy?

13F Pro's AI-powered analysis of Neuronetics, Inc. (STIM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STIM are available on the STIM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STIM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STIM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuronetics, Inc.'s investment landscape.